Cambiar Investors’s Harmony Biosciences HRMY Stock Holding History

Cambiar Investors’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-82,222	Closed	-$3.15M	–	151
2021 Q3	$3.15M	Sell	82,222 -21,861	-21%	-$704K	0.11%	95
2021 Q2	$2.94M	Buy	104,083 +29,035	+39%	+$871K	0.09%	116
2021 Q1	$2.48M	Buy	+75,048	New	+$2.63M	0.09%	133

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return

Cambiar Investors's HRMY Position: Q4 2021 in Review

Cambiar Investors sold out of Harmony Biosciences (HRMY) in Q4 2021, closing a stake of 82,222 shares — an estimated $3.15M sold.

Cambiar Investors first reported a position in HRMY in Q1 2021 and held it in 3 quarters. The position peaked at $3.15M in Q3 2021. 147 funds tracked by Wall St. Rank hold HRMY as of Q4 2021.

Cambiar Investors reported no remaining Harmony Biosciences position as of Q4 2021 after selling out during the quarter.
Cambiar Investors sold 82,222 Harmony Biosciences shares in Q4 2021, an estimated $3.15M.
Cambiar Investors first reported a position in Harmony Biosciences in Q1 2021 and held it in 3 quarters.
Cambiar Investors's Harmony Biosciences position peaked at $3.15M in Q3 2021.
147 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2021.

Based on Cambiar Investors's 13F filing for Q4 2021, filed 27 Jan 2022.